José Wilson Ramos Braga Junior

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute(More)
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one(More)
  • 1